Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
- PDF / 774,169 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 43 Downloads / 138 Views
ORIGINAL RESEARCH
Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis Jacqueline Nicholas . Huanxue Zhou . Chinmay Deshpande
Received: September 18, 2020 / Accepted: November 11, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: The severity of relapses varies in multiple sclerosis (MS) and may lead to a differential cost burden. This study aimed to characterize the direct healthcare costs associated with relapses in patients with MS by the level of relapse severity. Methods: This retrospective analysis used claims data extracted from the MarketScanÒ Databases from January 1, 2013 to March 31, 2017 (study period January 1, 2012 to March 31, 2018). Adult patients with at least one diagnosis of MS and 12 months of continuous enrollment prior to the first MS diagnosis to 12 months after the index date were included. On the basis of the severity of the relapse, patients were stratified into three cohorts: severe relapse (SR), mild/moderate relapse (MMR), and no relapse (NR). All-cause and MS-related costs were analyzed during the 12-month follow-up period. Group differences were assessed using descriptive and multivariate statistical analyses. J. Nicholas OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital, Columbus, OH, USA H. Zhou KMK Consulting Inc., Morristown, NJ, USA C. Deshpande (&) Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA e-mail: [email protected]
Results: In total, 8775 patients with MS were analyzed: 6341 (72%) in the NR cohort, 1929 (22%) in the MMR cohort, and 505 (6%) in the SR cohort. Overall, patients were mostly female (76%), mean age was 50 years, and 25% were on a disease-modifying therapy. Mean (standard deviation [SD]) all-cause and MS-related costs among patients with a relapse were higher vs patients without a relapse (all-cause $66,489 [$56,264] vs $41,494 [$48,417]; MS-related $48,700 [$43,364] vs $24,730 [$33,821]). Among patients with a relapse, the mean (SD) all-cause costs were $87,979 [$65,991] vs $60,863 [$51,998] and MS-related costs were $69,586 ($51,187) vs $43,233 [$39,292] for patients in the SR vs MMR cohorts, respectively. A similar trend for increase in cost by relapse severity was observed in the adjusted analysis. Conclusion: Total annual all-cause and MS-related costs increased with severity of the relapses. High-efficacy treatments might reduce the severity of the relapses, thereby reducing the cost of care in patients with MS. Keywords: Healthcare costs; Multiple sclerosis; Relapse; Severity
Adv Ther
Key Summary Points Why carry out this study? There is a need to better characterize total direct cost after the relapse in patients with MS using the most current data What did the study ask? The aim of this study was to evaluate annual cost of relapse by severity of relapse experienced by patients with MS What were the study outcomes/conclusions? Overall, this study highlights the cost burden incurred owing to MS relapses. The study provides a more accurate representation of cost burden of relaps
Data Loading...
